[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA30039B1 - Nouveaux derives de furopyrimidines a substitution acyclique et leur utilisation pour traiter des maladies cardiovasculaires - Google Patents

Nouveaux derives de furopyrimidines a substitution acyclique et leur utilisation pour traiter des maladies cardiovasculaires

Info

Publication number
MA30039B1
MA30039B1 MA31016A MA31016A MA30039B1 MA 30039 B1 MA30039 B1 MA 30039B1 MA 31016 A MA31016 A MA 31016A MA 31016 A MA31016 A MA 31016A MA 30039 B1 MA30039 B1 MA 30039B1
Authority
MA
Morocco
Prior art keywords
cardiovascular diseases
treating cardiovascular
acyclic substituted
novel acyclic
furopyrimidine derivatives
Prior art date
Application number
MA31016A
Other languages
English (en)
Inventor
Thomas Lampe
Eva-Maria Becker
Raimund Kast
Hartmut Beck
Mario Jeske
Joachim Schuhmacher
Friederike Stoll
Martina Klein
Metin Akbaba
Andreas Knorr
Johannes-Peter Stasch
Lars Baerfacker
Alexander Hillisch
Gunter Karig
Mark Meininghaus
Karl-Heinz Schlemmer
Rudolf Schohe-Loop
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA30039B1 publication Critical patent/MA30039B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Nouveaux dérivés de furopyrimidine substitués de manière acyclique, et leurs applications La présente demande concerne des nouveaux dérivés de furopyrimidine substitués de manière acyclique, des procédés de production de ceux-ci, et leurs applications pour le traitement et/ou la prophylaxie de maladies, et leurs applications pour la production de produits médicinaux, pour le traitement et/ou la prophylaxie de maladies, en particulier, pour le traitement et/ou la prophylaxie de maladies cardiovasculaires.
MA31016A 2005-12-21 2008-06-11 Nouveaux derives de furopyrimidines a substitution acyclique et leur utilisation pour traiter des maladies cardiovasculaires MA30039B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005061170A DE102005061170A1 (de) 2005-12-21 2005-12-21 Neue, acyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung

Publications (1)

Publication Number Publication Date
MA30039B1 true MA30039B1 (fr) 2008-12-01

Family

ID=37876878

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31016A MA30039B1 (fr) 2005-12-21 2008-06-11 Nouveaux derives de furopyrimidines a substitution acyclique et leur utilisation pour traiter des maladies cardiovasculaires

Country Status (32)

Country Link
US (1) US8183246B2 (fr)
EP (1) EP1966217B1 (fr)
JP (1) JP5254032B2 (fr)
KR (1) KR101429777B1 (fr)
CN (1) CN101384603B (fr)
AR (1) AR058108A1 (fr)
AU (1) AU2006334856B2 (fr)
BR (1) BRPI0620317A2 (fr)
CA (1) CA2633701C (fr)
CR (1) CR10092A (fr)
DE (1) DE102005061170A1 (fr)
DK (1) DK1966217T3 (fr)
DO (1) DOP2006000280A (fr)
EC (1) ECSP088569A (fr)
ES (1) ES2418855T3 (fr)
GT (1) GT200800117A (fr)
HK (1) HK1130054A1 (fr)
IL (1) IL192062A0 (fr)
MA (1) MA30039B1 (fr)
NO (1) NO20082986L (fr)
NZ (1) NZ569214A (fr)
PE (1) PE20071168A1 (fr)
PL (1) PL1966217T3 (fr)
PT (1) PT1966217E (fr)
RU (1) RU2454419C2 (fr)
SV (1) SV2009002953A (fr)
TN (1) TNSN08279A1 (fr)
TW (1) TWI405764B (fr)
UA (1) UA94080C2 (fr)
UY (1) UY30046A1 (fr)
WO (1) WO2007079862A1 (fr)
ZA (1) ZA200805385B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007019691A1 (de) * 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007027799A1 (de) * 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte Furopyrimidine und ihre Verwendung
DE102007051762A1 (de) * 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
DE102007054786A1 (de) * 2007-11-16 2009-05-20 Bayer Healthcare Ag Trisubstituierte Furopyrimidine und ihre Verwendung
US9505772B2 (en) 2012-05-10 2016-11-29 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2013168759A1 (fr) 2012-05-10 2013-11-14 武田薬品工業株式会社 Composé cyclique aromatique
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
US11434247B1 (en) 2017-11-27 2022-09-06 Dart Neuroscience Llc Substituted furanopyrimidine compounds as PDE1 inhibitors
EP4306529A3 (fr) 2019-05-13 2024-04-10 Relay Therapeutics, Inc. Inhibiteurs de fgfr et leurs procédés d'utilisation
KR102094337B1 (ko) 2019-10-01 2020-03-27 안문호 금속이물질 제거장치

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577420A (en) * 1968-01-05 1971-05-04 Pfizer Certain 4-aminofuro(2,3-d)pyrimidines
EP1018514B1 (fr) 1998-07-22 2004-05-12 Daiichi Suntory Pharma Co., Ltd. INHIBITEURS DE NF-$g(k)B CONTENANT DES DERIVES D'INDANE EN TANT QU'INGREDIENT ACTIF
EP1181296A1 (fr) 1999-06-03 2002-02-27 Abbott Laboratories Composes anti-inflammatoires inhibant l'adhesion cellulaire
HUP0104841A3 (en) 1999-09-17 2002-07-29 Daiichi Suntory Pharma Co Ltd Medicaments containing benzoquinone- or condensed pyrimidine derivatives as active ingredient for treating of myocarditis, dilated cardiomyopathy and cardiac insufficiency
CA2449188A1 (fr) 2001-05-14 2002-11-21 Novartis Ag Oxazolopyrimidines et furopyrimidines et utilisation dans des agents pharmaceutiques contre les tumeurs
DE10141212A1 (de) * 2001-08-22 2003-03-06 Bayer Ag Neue 4-Aminofuropyrimidine und ihre Verwendung
EP1425284A2 (fr) 2001-09-11 2004-06-09 Smithkline Beecham Corporation Composes chimiques
DE10148883A1 (de) 2001-10-04 2003-04-10 Merck Patent Gmbh Pyrimidinderivate
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ddr2 티로신키나아제 활성 저해제
AU2005252440A1 (en) 2004-06-10 2005-12-22 Xention Discovery Limited Furanopyrimidine compounds effective as potassium channel inhibitors
JP2008505084A (ja) 2004-06-29 2008-02-21 アムゲン インコーポレイティッド フラノピリミジン

Also Published As

Publication number Publication date
CA2633701A1 (fr) 2007-07-19
JP5254032B2 (ja) 2013-08-07
NZ569214A (en) 2011-07-29
US20090318475A1 (en) 2009-12-24
TWI405764B (zh) 2013-08-21
PE20071168A1 (es) 2008-02-07
DK1966217T3 (da) 2013-08-05
CN101384603A (zh) 2009-03-11
RU2454419C2 (ru) 2012-06-27
AU2006334856B2 (en) 2013-04-04
PT1966217E (pt) 2013-07-12
PL1966217T3 (pl) 2013-09-30
ES2418855T3 (es) 2013-08-16
ZA200805385B (en) 2009-10-28
AU2006334856A1 (en) 2007-07-19
IL192062A0 (en) 2008-12-29
CN101384603B (zh) 2012-08-01
NO20082986L (no) 2008-07-02
JP2009520713A (ja) 2009-05-28
SV2009002953A (es) 2009-04-28
KR101429777B1 (ko) 2014-08-19
AR058108A1 (es) 2008-01-23
RU2008129363A (ru) 2010-01-27
US8183246B2 (en) 2012-05-22
EP1966217B1 (fr) 2013-05-08
UY30046A1 (es) 2007-07-31
ECSP088569A (es) 2008-08-29
CA2633701C (fr) 2014-05-27
WO2007079862A1 (fr) 2007-07-19
TNSN08279A1 (en) 2009-10-30
BRPI0620317A2 (pt) 2011-11-08
KR20080081323A (ko) 2008-09-09
EP1966217A1 (fr) 2008-09-10
CR10092A (es) 2008-10-08
HK1130054A1 (en) 2009-12-18
UA94080C2 (ru) 2011-04-11
DOP2006000280A (es) 2007-07-31
TW200745132A (en) 2007-12-16
DE102005061170A1 (de) 2007-07-05
GT200800117A (es) 2009-12-16

Similar Documents

Publication Publication Date Title
MA30039B1 (fr) Nouveaux derives de furopyrimidines a substitution acyclique et leur utilisation pour traiter des maladies cardiovasculaires
DE502005006149D1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
MA33123B1 (fr) 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation
TW200736213A (en) Dicarboxylic acid derivatives and their use
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
MA42376B1 (fr) Dérivés d'oxopyridine substitués
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MA44851B1 (fr) Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations
MA35039B1 (fr) Dérivés ramifiés de l'acide 3-phénylpropionique et leur utilisation
BRPI0410454A (pt) composições e compostos imunossupressores
TW200505428A (en) Immunosuppressant compounds and compositions
MXPA05012461A (es) Compuestos y composiciones inmunosupresores.
MA34019B1 (fr) Aryltriazolone liée à un bis-aryle et son utilisation
WO2009068214A3 (fr) Pipéridines à substitution hétéroaryl
ATE453642T1 (de) Substituierte phenylaminopyrimidine
EA200701648A1 (ru) Замещённые пирролы и имидазолы, содержащие их композиции, способ получения и применение
TW200621765A (en) Substituted phenylaminothiazoles and their use
MY150931A (en) Substituted oxazolidinones and their use
DE502007006625D1 (de) 3-cyano-5-thiazaheteroaryl-dihydropyridine und ihrnkungen
GEP20135733B (en) Novel diazeniumdiolate derivatives, their preparation method and pharmaceutical compositions containing them
HK1112228A1 (en) Substituted azachinzolines having an antiviral action
DE502007004579D1 (de) Aryl-substituierte heterozyklen und ihre verwendung
ATE524463T1 (de) 4-chromenonyl-1,4-dihydropyridincarbonitrile und ihre verwendung
MX2024003249A (es) Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.
ATE410443T1 (de) Heterocyclyl-substituierte nonadepsipeptide